Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Capital Expenditures (2019 - 2025)

Avidity Biosciences' Capital Expenditures history spans 7 years, with the latest figure at $9.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 245.11% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $13.3 million, up 288.99%, while the annual FY2025 figure was $13.3 million, 288.99% up from the prior year.
  • Capital Expenditures reached $9.6 million in Q4 2025 per RNA's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9.6 million in Q4 2025 to a low of -$2.2 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $1.3 million, with a median of $622000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: surged 5150.0% in 2021, then plummeted 1959.81% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $3.6 million in 2021, then crashed by 148.25% to -$1.7 million in 2022, then soared by 329.31% to $4.0 million in 2023, then plummeted by 30.6% to $2.8 million in 2024, then surged by 245.11% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Capital Expenditures are $9.6 million (Q4 2025), $1.4 million (Q3 2025), and -$1.4 million (Q2 2025).